Canada markets closed

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1485-0.0162 (-9.85%)
At close: 3:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1647
Open0.1654
BidN/A x N/A
AskN/A x N/A
Day's Range0.1395 - 0.1654
52 Week Range0.1395 - 0.1654
Volume153,937
Avg. VolumeN/A
Market Cap5.014M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Mindleap Health Implements HIPAA Compliance Standards and Appoints Former Canadian Ministry of Health Telemedicine Expert as Head of Program Management

    DENVER, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that its wholly-owned subsidiary, Mindleap Health (“Mindleap”), has implemented a comprehensive information security rollout of next-generation cyber-security solutions to meet HIPAA compliance standards. Mindleap also welcomes its new Director of Program Management, Dyson Walker, who will support Mindleap in improving its platform and meeting and exceeding all relevant laws and regulations. HIPAA Compliance CertificationThe Health Insurance Portability and Accountability Act, also known as HIPAA, is US legislation that provides security provisions to safeguard medical information. The Mindleap software development and security team have undergone a comprehensive multi-step verification process to ensure full HIPAA compliance and adherence with the following regulations: * HIPAA Privacy Rule * HIPAA Security Rule * HITECH Act * Omnibus Rule * Breach Notification RuleMindleap Chief Technology Officer, Simon Abou-Antoun, commented, “Mindleap recognizes the immense responsibility that comes with collecting, storing, and managing personal data about users' mental health. Given the highly sensitive nature of this data, we owe it to ourselves, our users, and our partners to establish secure processes and systems that protect users. Our system offers secure communication, is compliant with HIPAA and we are pleased to have implemented next generation cybersecurity platforms to ensure maximum protection of our users’ data."Next-Gen Cyber Security ImplementationMindleap has put together a comprehensive and fully operational security strategy and rollout to ensure administrative, physical, and technical safeguards are in place in order to protect the confidentiality, integrity, and availability of its sensitive data, including, without limitation, protected health information.The next-generation security solutions include virus and exploit protection, encryption, network security, email security as well as a system for secure communication that protects the integrity of ePHI. (Electronic Personal Health Information) and a system of monitoring communications containing ePHI to prevent accidental or malicious breaches. Mindleap’s policies for securing data are following established and modern healthcare protocols all while being able to provide a secure and seamless service to clients.Chief Compliance Officer, Dyson WalkerMr. Walker is a proven IT professional with a wide range of experience managing large, complex projects in Europe, Asia and North America. Dyson has spent over 15 years in the Canadian Health System, 10 of which entailed working the British Columbia Ministry of Health, Provincial Telehealth Office (PTO) whose mandate was to support the expansion of telehealth in the Province. During Dyson’s tenure at the Ministry, some of his major achievements were: * Successfully represented the Government of British Columbia on two federal pan- Canadian telehealth initiatives with participation by 12 of the 13 Canadian jurisdictions. Each initiative resulted in signed national agreements wtih major vendors and significantly accelerated the expansion of telehealth in Canada.   * Worked extensively with BC First Nations and local health authorities to support improved health care access via telehealth to their rural, underserved communities. Dyson was engaged with First Nations executive leadership at the federal, provincial and community levels. These First Nations led initiatives resulted in improved health outcomes.   * Acted as Program Manager for the $52M Home Health Monitoring Enabling Services (HHMES) initiative, a public, private partnership (PPP) between the BC Government and TELUS. HHMES comprised of six provincial technology projects that would accelerate adoption and expansion of telehealth in the Province. As Program Manager, Mr. Walker was responsible for four of the six projects with an estimated value of $20M.Mindleap founder and CEO, Nikolai Vassev, commented: “We have taken every step and precaution in guaranteeing privacy and confidentiality on our platform and are incredibly pleased with the progress our security and compliance team have made in such a short time. We are also thrilled to have an experienced executive like Dyson Walker and lead our efforts in improving our platform.”About Mydecine Innovations Group, Inc.Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.About Mindleap Health Inc.Mindleap is developing an advanced digital health platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking. This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.Learn about Mindleap HealthLearn about The Past and Future of Psychedelics as a MedicineApply to become a Specialist on MindleapFor further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.On behalf of the Board of Directors: Joshua Bartch, Chief Executive Officer contact@mydecineinc.comCorp Communication: Charles Lee, Investor Relations corp@mydecineinc.com +1 (250) 488-6728Public Relations: Cynthia Salarizadeh, PR pr@mydecineinc.comThe Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward- looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

  • GlobeNewswire

    Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets

    DENVER, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value. Topics that the special committee will discuss include, but limited to, a potential spin out of certain company assets. Currently, the company owns and operates a number of growing US assets in the THC-cannabis and hemp-CBD space, along with distribution, that are being evaluated and assessed as potential spin out options with respect to the Mydecine's non-fungi related assets. Current shareholders would receive automatic shares of the SpinCo.“We are constantly looking at ways to increase our shareholder value. Our company has grown at an incredible rate and is quickly establishing itself as a leader in the functional mushroom and psychedelic medicine space,” said Mydecine Chief Executive Officer, Joshua Bartch. “With that said, the company has a number of highly valuable assets that could potentially create larger shareholder value if they were spun out into a more focused stand-alone vehicle. We are currently evaluating a number of potential options and partners to accomplish this goal."Further information will be provided as this opportunity develops.About Mydecine Innovations Group Inc. Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.For further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.On behalf of the Board of Directors: Joshua Bartch, Chief Executive Officer contact@mydecineinc.com Corp Communication: Charles Lee, Investor Relations corp@mydecineinc.com +1 (250) 488-6728Public Relations: Cynthia Salarizadeh, PR pr@mydecineinc.com The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

  • GlobeNewswire

    Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days

    DENVER, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine", “MIG” or the "Company") is pleased to announce that its shareholders have agreed to extend lock-up restrictions in respect to 35,737,460 shares of the Company that were due to be released on September 6, 2020, for an additional 120 days. Under the terms of the agreement, 35,737,460 common shares of the firm will see their escrow conditions extended an additional 120 days; due to be released on Jan. 8, 2021.The MIG executive team would like to thank its shareholders for creating this opportunity.“We would like to thank our loyal and trusting shareholders that participated in this extended lock up,” commented Josh Bartch, CEO & Director, Mydecine Innovations Group. “This agreement demonstrates the bullish nature of our investors and their belief in our long term strategy. We are pleased with the initial numbers, and expect more to come in the following days.”About Mydecine Innovations Group Inc. Mydecine Innovations Group™ is a publicly traded life sciences parent company with offices in Denver, CO and Vancouver, BC. Mydecine™ is dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development, including synthesis, genetic research, import/export, delivery system design, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.For further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.On behalf of the Board of Directors: Joshua Bartch, Chief Executive Officer contact@mydecineinc.comCorp Communication: Charles Lee, Investor Relations corp@mydecineinc.comPublic Relations: Cynthia Salarizadeh, Public Relations pr@mydecineinc.comThe Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.